Kingstone Capital Partners Texas LLC Takes $227,000 Position in Emergent Biosolutions Inc. $EBS

Key Points

• Kingstone Capital Partners Texas LLC purchased 35,520 shares of Emergent Biosolutions Inc. for approximately $227,000, increasing their ownership to about 0.07%.
• Emergent Biosolutions recently reported an EPS of $0.16, surpassing analysts' expectations, although revenue of $140.90 million fell short of estimates.
• Analysts have mixed sentiments on Emergent Biosolutions, with one firm downgrading its rating from "buy" to "hold," while another has maintained a "buy" rating with a target price of $15.00.

Kingstone Capital Partners Texas LLC bought a new position in shares of Emergent Biosolutions Inc. (NYSE:EBS - Free Report) in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund bought 35,520 shares of the biopharmaceutical company's stock, valued at approximately $227,000. Kingstone Capital Partners Texas LLC owned 0.07% of Emergent Biosolutions at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. SBI Securities Co. Ltd. increased its holdings in Emergent Biosolutions by 95.1% during the first quarter. SBI Securities Co. Ltd. now owns 12,951 shares of the biopharmaceutical company's stock worth $63,000 after buying an additional 6,313 shares during the last quarter. Corton Capital Inc. acquired a new position in shares of Emergent Biosolutions during the first quarter valued at about $70,000. EP Wealth Advisors LLC lifted its position in shares of Emergent Biosolutions by 33.1% during the first quarter. EP Wealth Advisors LLC now owns 15,249 shares of the biopharmaceutical company's stock valued at $74,000 after purchasing an additional 3,790 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in Emergent Biosolutions by 40.4% in the 1st quarter. Bank of New York Mellon Corp now owns 17,003 shares of the biopharmaceutical company's stock worth $83,000 after acquiring an additional 4,894 shares during the last quarter. Finally, HBK Sorce Advisory LLC bought a new position in shares of Emergent Biosolutions in the first quarter valued at approximately $131,000. 78.40% of the stock is currently owned by institutional investors.

Emergent Biosolutions Price Performance

Shares of NYSE:EBS traded down $0.06 during midday trading on Monday, hitting $8.16. The company's stock had a trading volume of 746,332 shares, compared to its average volume of 958,394. Emergent Biosolutions Inc. has a 12-month low of $4.02 and a 12-month high of $12.73. The company has a debt-to-equity ratio of 1.25, a quick ratio of 3.00 and a current ratio of 5.66. The company has a market cap of $435.07 million, a P/E ratio of 3.33 and a beta of 2.03. The business's 50 day simple moving average is $7.81 and its 200 day simple moving average is $6.51.

Emergent Biosolutions (NYSE:EBS - Get Free Report) last issued its earnings results on Wednesday, August 6th. The biopharmaceutical company reported $0.16 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.42. The business had revenue of $140.90 million during the quarter, compared to analysts' expectations of $148.55 million. Emergent Biosolutions had a net margin of 16.38% and a return on equity of 24.63%. On average, analysts forecast that Emergent Biosolutions Inc. will post -0.63 EPS for the current year.

Insider Transactions at Emergent Biosolutions

In related news, Director Kathryn C. Zoon sold 7,086 shares of the stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $8.87, for a total transaction of $62,852.82. Following the completion of the sale, the director directly owned 71,799 shares of the company's stock, valued at $636,857.13. This represents a 8.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Donald W. Degolyer sold 7,844 shares of the stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $8.65, for a total value of $67,850.60. Following the completion of the transaction, the director owned 137,659 shares of the company's stock, valued at $1,190,750.35. This trade represents a 5.39% decrease in their position. The disclosure for this sale can be found here. 3.20% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of analysts recently weighed in on the company. HC Wainwright restated a "buy" rating and issued a $15.00 target price on shares of Emergent Biosolutions in a research report on Wednesday, September 3rd. Wall Street Zen lowered shares of Emergent Biosolutions from a "buy" rating to a "hold" rating in a report on Saturday, August 9th. Two research analysts have rated the stock with a Buy rating, According to MarketBeat, Emergent Biosolutions presently has a consensus rating of "Buy" and an average target price of $13.50.

Emergent Biosolutions Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.